07:00 , Aug 6, 2015 |  BC Innovations  |  Product R&D

Impede a fever

A team at the Massachusetts Institute of Technology has developed an antibody that could treat dengue infections caused by all four serotypes of the virus, and might be able to prevent the disease as well....
08:00 , Dec 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Dengue fever Dengue virus envelope protein E (DENV_gp1) In vitro studies have identified residues of the dengue virus envelope protein that could be targeted...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Altravax management update

Altravax Inc. , Fargo, N.D.   Business: Infectious   Hired: Sean Du as COO, formerly executive director at Simcere Pharmaceutical Group 's Institute of Vaccine Research  ...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Altravax, National Institutes of Health infectious news

Altravax received $1.2 million in two equal Advanced Technology Small Business Innovation Research grants from NIH's National Institute of Allergy and Infectious Diseases for research on vaccines to prevent dengue fever and to treat chronic...
08:00 , Mar 1, 2010 |  BC Week In Review  |  Company News

AltraVax, Maxygen deal

Newco AltraVax received exclusive, worldwide rights to use Maxygen's MolecularBreeding technology for vaccine identification and development. The technology uses directed evolution, a process of recombining genes homologous to target proteins to create new proteins. AltraVax...